Navigation Links
Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
Date:6/10/2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced that Oramed was chosen to present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009. The presentation will be given by Mr. Nadav Kidron, President and CEO of Oramed, on Tuesday, June 16th during the BioPharma Session at 12:30 p.m. (local time) at the David Intercontinental Hotel in Tel-Aviv, Israel.

"The selection of Oramed as one of the companies to present at the ILSI-Biomed is a great opportunity that allows us to present our company to the leading biomedical, health care and life science professionals from all over the world," said Nadav Kidron, Oramed CEO.

For more information about the upcoming ILSI Biomed conference, please visit http://www2.kenes.com/biomed/Pages/Home.aspx

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Business Development Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    Office: +972-2-566-0001
    Email: tara@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
3. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
4. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
5. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
9. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
10. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
11. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... now offer a comprehensive in-house dental plan for all patients. Understanding that budget ... plan that gives patients a number of perks, including discounts on many valuable ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... mental health treatment has announced the opening of a new eating disorder treatment ... and intensive outpatient treatment for adults and adolescents, both males and females ages ...
(Date:11/30/2016)... Warrington, U.K. (PRWEB) , ... November 30, 2016 ... ... to address the tech functions and stylish design wanted by today’s consumers at ... , Cronovo Co-Founder Darin Philip says the new watch is “a game changer” ...
Breaking Medicine News(10 mins):